With Merck’s COVID Antiviral Announcement, Can the Pharma Pipeline Build Treatment Momentum?

 

At the start of the month, pharmaceutical company Merck dropped big news: it has developed a COVID antiviral drug that would cut hospitalization and mortality risks by 50%. In the drug’s study, patients taking the placebo pill saw 14% hospitalization rate and eight deaths, the trial group with Merck’s drug had only 7% hospitalized, and zero deaths.

But this appears to be just the tip of the iceberg: Kaiser Health News reports at least three COVID antiviral candidates, including Merck’s, going through late-stage clinical trials, meaning a variety of COVID drugs could be on patient’s prescriptions here soon. What’ll be some of the positive domino effects to come from approval of COVID antivirals, not only on the pharmaceutical production pipeline, but on the general population’s health? Ira Leiderman, managing director of the healthcare practice at Cassel Salpeter & Co., gave MarketScale his take on the coming treatments.

Follow us on social media for the latest updates in B2B!

Latest

Breaking Glass with Nancy Novak: Confronting Implicit Bias in the Workplace
October 18, 2021
“Implicit bias isn’t always visible. It’s not always as concrete as bringing in people with differences.” Implicit bias is subconscious and not recognized by those impacted by it. So, how can companies Read more
Impressions: Hot Trends in Self-Storage for 2021
October 18, 2021
  RV and boat purchases are up, creating new opportunities for self-storage tenants and self-storage operators offering enhanced protection on renters’ valuable assets. Jacquelyn Nash, Sr. Account Executive Read more
Math Proficiency Scores Decline Nationwide
As Math Proficiency Scores Decline Nationwide, How Should Curriculum Shift?
October 18, 2021
  Disruptions to education during the pandemic had a serious impact on knowledge retention and student performance, and it's bearing out in assessment numbers. Whether it's a fault in the Read more